Last reviewed · How we verify
Metoclopramide hydrochloride monohydrate
Metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone and enhances acetylcholine effects on gastric muscle to increase gastric contractions and accelerate gastric emptying.
Metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone and enhances acetylcholine effects on gastric muscle to increase gastric contractions and accelerate gastric emptying. Used for Nausea and vomiting, Gastroesophageal reflux disease (GERD), Diabetic gastroparesis.
At a glance
| Generic name | Metoclopramide hydrochloride monohydrate |
|---|---|
| Also known as | Reglan, primperan injection |
| Sponsor | CM Chungmu Hospital |
| Drug class | Dopamine antagonist / Antiemetic / Prokinetic agent |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Metoclopramide acts as a dopamine antagonist at the chemoreceptor trigger zone, suppressing nausea and vomiting signals. Simultaneously, it enhances acetylcholine sensitivity in gastric smooth muscle, promoting stronger contractions and faster movement of food from the stomach into the small intestine. This dual mechanism makes it effective for both antiemetic and prokinetic purposes.
Approved indications
- Nausea and vomiting
- Gastroesophageal reflux disease (GERD)
- Diabetic gastroparesis
- Post-operative nausea and vomiting
Common side effects
- Tardive dyskinesia
- Restlessness / Akathisia
- Drowsiness
- Diarrhea
- Headache
- Fatigue
Key clinical trials
- Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC) (PHASE4)
- Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: